We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Is there a role for 'modified VAD' in the treatment of multiple myeloma?
- Authors
Agazzi, A.; Sammassimo, S.; Laszlo, D.; Liptrott, S. J.; Cascio, R.; Alietti, A.; Rabascio, C.; Mancuso, P.; Pruneri, G.
- Abstract
VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its derivative, lenalidomide) and bortezomib. After the excellent results obtained by the novel agents, VAD can no longer be proposed in preparation to autologous transplantation, although there are still indications that VAD remains useful and clinically relevant in the initial treatment of symptomatic multiple myeloma.
- Subjects
MULTIPLE myeloma treatment; MYELOMA (Book); TUMOR markers; THALIDOMIDE; ALKYLATING agents; AUTOTRANSPLANTATION
- Publication
Ecancermedicalscience, 2009, Vol 3, p1
- ISSN
1754-6605
- Publication type
Article
- DOI
10.3332/ecancer.2009.136